Brief: Larimar Reports Positive Long-Term Data, Updates Nomlabofusp Program for Friedreich’s Ataxia

Larimar Therapeutics

29/09/2025 12:19

Sept 29 (Reuters) - Larimar Therapeutics Inc LRMR.O:

LARIMAR THERAPEUTICS ANNOUNCES POSITIVE DATA FROM ONGOING LONG-TERM OPEN LABEL STUDY AND UPDATES TO NOMLABOFUSP PROGRAM FOR FRIEDREICH’S ATAXIA

LARIMAR THERAPEUTICS INC - BLA SUBMISSION FOR ACCELERATED APPROVAL TARGETED IN Q2 2026

Source text: ID:nGNX79FfMj

Further company coverage: LRMR.O

 ((Reuters.Briefs@thomsonreuters.com;))